On July 17, 2018, the FDA issued a press release announcing the voluntary recall of several drug products containing the active ingredient valsartan due to the discovery it contained N-nitrosodimethylamine (NDMA), a carcinogen. The American Cancer Association defines carcinogens as substances and exposures that can lead to cancer. At the time of the recall, over 1.5 million Americans were using valsartan daily.